Edition:
United Kingdom

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

17.90USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$17.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
286,463
52-wk High
$21.47
52-wk Low
$16.06

Latest Key Developments (Source: Significant Developments)

Halozyme Therapeutics Q2 Loss Per Share $0.16
Tuesday, 7 Aug 2018 

Halozyme Therapeutics Inc ::HALOZYME REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.16.Q2 REVENUE $35.2 MILLION VERSUS I/B/E/S VIEW $30.1 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.ACHIEVEMENT OF TARGET NUMBER OF PROGRESSION-FREE SURVIVAL EVENTS IN HALO-301 ON TRACK FOR DECEMBER 2018 TO FEBRUARY 2019.SEES 2018 NET REVENUE $125 MILLION TO $135 MILLION.  Full Article

Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Halozyme Therapeutics Inc ::HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018.HALOZYME THERAPEUTICS INC - ‍ FORECASTS POTENTIAL ROYALTY REVENUE FOR ENHANZE TO REACH NEARLY $1 BILLION IN 2027 ​.HALOZYME THERAPEUTICS INC - ‍EXPECTS ADDITIONAL PARTNERS TO BEGIN THREE PHASE 1 STUDIES WITH NEW TARGETS FOR ENHANZE​ IN 2018.  Full Article

Halozyme reports Q3 EPS of $0.02
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Halozyme Therapeutics Inc :Halozyme reports third quarter 2017 results.Q3 earnings per share $0.02.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q3 revenue $63.7 million versus i/b/e/s view $59 million.Sees FY 2017 ‍net revenue of $265 million to $280 million​.Qtrly ‍ cash, cash equivalents & marketable securities were $316.9 million at Sept. 30, 2017, versus $297.5 million at June 30, 2017​.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

BRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement

* GOT NOTICE FROM HALOZYME THERAPEUTICS OF TERMINATION OF COLLABORATION, LICENCE AGREEMENT RELATING TO HALOZYME'S USE OF CO'S THIOBRIDGE LINKER TECH Source text for Eikon: Further company coverage: